Brief: Liquidia says US FDA Grants Tentative Approval Of Yutrepia For Patients With Pulmonary Arterial Hypertension And Pulmonary Hypertension Associated With Interstitial Lung Disease

Liquidia

19/08/2024 11:53

Aug 19 (Reuters) - Liquidia Corp  LQDA.O :
    * U.S. FDA GRANTS TENTATIVE APPROVAL OF YUTREPIA™
(TREPROSTINIL)
INHALATION POWDER FOR PATIENTS WITH PULMONARY ARTERIAL
HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH
INTERSTITIAL LUNG DISEASE (PH-ILD)
    * LIQUIDIA - FINAL APPROVAL OF YUTREPIA FOR PAH AND PH-ILD
MAY
OCCUR AFTER EXPIRATION OF 3-YEAR REGULATORY EXCLUSIVITY FOR
TYVASO DPI ON MAY 23, 2025
    * LIQUIDIA CORP:  FDA CONFIRMED THAT AMENDMENT TO ADD PH-ILD
TO
YUTREPIA NDA MEETS REQUIREMENTS FOR APPROVAL UNDER FEDERAL FOOD,
DRUG, AND COSMETIC ACT

Source text for Eikon:  ID:nGNX9Jh20n 
Further company coverage:  LQDA.O 

 ((Reuters.Briefs@thomsonreuters.com;))